The French Competition Authority orders interim measures particularly to address denigration practices implemented in the pharmaceutical sector (Arrow / Schering-Plough)

Press Release published on the official website of the French Competition Authority.

The Conseil de la concurrence orders Schering Plough laboratory to remind doctors and pharmacists the exact bioequivalence of its brand name drug Subutex® with competing generic drugs* Following a complaint by Arrow Génériques company for practices implemented by Schering Plough laboratory, at the launching of the generic product Subutex® on the market, the Conseil de la concurrence has just ordered an interim measure before reaching its decision on the merits. The practices concerned Buprenorphine is a

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

French Competition Authority, The French Competition Authority orders interim measures particularly to address denigration practices implemented in the pharmaceutical sector (Arrow / Schering-Plough), 11 December 2007, e-Competitions Bulletin December 2007, Art. N° 66212

Visites 74

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues